Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Arbutus Biopharma's Enterprise Value is $818.0 Mil.
Arbutus Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-34.4 Mil. Therefore, Arbutus Biopharma's EV-to-OCF for today is -23.81.
The historical rank and industry rank for Arbutus Biopharma's EV-to-OCF or its related term are showing as below:
ABUS'
s EV-to-OCF Range Over the Past 10 Years
Min: -24.92 Med: -5.13 Max: 0.3
Current: -23.81
During the past 13 years, the highest EV-to-OCF of Arbutus Biopharma was 0.30. The lowest was -24.92. And the median was -5.13.
ABUS's EV-to-OCF is ranked better than 83.3% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs ABUS: -23.81
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arbutus Biopharma's PE Ratio (TTM) for today is calculated as:
Arbutus Biopharma's share price for today is $4.62.
Arbutus Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.830.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Arbutus Biopharma EV-to-OCF Related Terms
Arbutus Biopharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arbutus Biopharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's EV-to-OCF falls into.
Arbutus Biopharma's current Enterprise Value is $818.0 Mil.
Arbutus Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (ABUS) has a EV-to-OCF of -23.81 as of Aug. 09, 2026. According to the industry distribution chart, Arbutus Biopharma ranks #235 out of 1407 companies in the Biotechnology industry, placing it in the top 16.7%.
Is Arbutus Biopharma's EV-to-OCF too high?
Arbutus Biopharma's current EV-to-OCF is -23.81. Based on the distribution chart, Arbutus Biopharma ranks #235 out of 1407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's EV-to-OCF compare to TBPH and ANNX?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #235 out of 1407 companies for EV-to-OCF. This places Arbutus Biopharma in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Arbutus Biopharma's current EV-to-OCF is -23.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $50.27, compared to a current price of $4.62 — trading 90.8% below its estimated fair value. The current EV-to-OCF is -23.81. Arbutus Biopharma's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current EV-to-OCF is -23.81 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.62 is trading 90.8% below its estimated GF Value™ of $50.27.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
EV-to-OCF: -23.81
GF Value™: $50.27 vs. price of $4.62 (90.8% below fair value)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score
Get the complete analysis for ABUS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
